Daxor (FRA:DX5) ROCE %: % (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:DX5 Daxor Corp FRA:DX5
51 GF Score
Price €7.90
GF Value €29.07
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Daxor ROCE %?

Daxor FRA:DX5 -3.66% 51 ROCE % is % as of Dec. 2025. GuruFocus rates FRA:DX5 with a GF Score™ of 51/100 and a GF Value™ of €29.07 (Possible Value Trap). The stock has 1 warning sign investors should review.

ROCE % does not apply to banks and insurance companies.

FRA:DX5
51GF Score
Daxor Corp FRA:DX5
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of % mean?
Daxor (FRA:DX5) has a ROCE % of % as of Dec. 2025.
Is Daxor's ROCE % too high?
Daxor's current ROCE % is %. Overall, Daxor has a GF Score™ of 51/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Daxor's ROCE % compare to POCI and NEPH?
Daxor's ROCE % of % can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 3.25. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 3.25, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 3.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daxor's current ROCE % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daxor stock overvalued right now?
Based on GuruFocus' analysis, Daxor (FRA:DX5) is currently considered Possible Value Trap. The stock's GF Value™ is €29.07, compared to a current price of €7.90 — trading 72.8% below its estimated fair value. The current ROCE % is %. Daxor's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Daxor (FRA:DX5), the current ROCE % is % as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Daxor (FRA:DX5) Overvalued in 2026?

Based on GuruFocus' analysis, Daxor stock appears to be undervalued. The current stock price of €7.90 is trading 72.8% below its estimated GF Value™ of €29.07. GuruFocus considers Daxor to be Possible Value Trap.

Key valuation signals for FRA:DX5:

  • ROCE %: %
  • GF Value™: €29.07 vs. price of €7.90 (72.8% below fair value)
  • GF Score™: 51/100 with 1 warning sign

No single metric tells the full story. See the FRA:DX5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Daxor Business Description

Other Exchanges DXR:USA
Address 107 Meco Lane, Oak Ridge, TN, USA, 37830
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
51GF Score

Get the complete analysis for FRA:DX5

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€7.90
Price
€29.07
GF Value